Kathleen Wilson, MD
Internal Medicine · Salt Lake City, UTNPI 1477515690
Payments from drug & device makers
Across 156 payments — averaging $15.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$451
- Astellas Pharma US Inc$258
- Boehringer Ingelheim$250
- AbbVie$198
- Amgen$171
- Lilly USA, LLC$164
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,493100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 30 | $451 |
| Astellas Pharma US Inc | 16 | $258 |
| Boehringer Ingelheim | 14 | $250 |
| AbbVie(2 entities) | 10 | $198 |
| Amgen | 12 | $171 |
| Lilly USA, LLC | 10 | $164 |
| Novo Nordisk | 7 | $95 |
| Pfizer | 5 | $86 |
| Lifescan, Inc. | 6 | $84 |
| Sanofi-aventis U.S. LLC | 5 | $69 |
| Corcept Therapeutics | 3 | $62 |
| GSK | 4 | $61 |
| Gilead | 3 | $60 |
| Johnson & Johnson(2 entities) | 4 | $54 |
| Novartis | 3 | $49 |
| E.r. Squibb & Sons, L.L.C. | 3 | $46 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
| Biohaven Pharmaceuticals, Inc. | 1 | $32 |
| Ferring Pharmaceuticals Inc. | 2 | $28 |
| Amarin Pharma, Inc. | 2 | $27 |
| Sanofi Pasteur Inc. | 2 | $27 |
| AstraZeneca | 2 | $26 |
| Sequel Med Tech, LLC | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Bayer | 1 | $16 |
| Mylan Specialty L.p. | 1 | $15 |
| Shionogi Inc | 1 | $15 |
| Cumberland Pharmaceuticals, Inc. | 1 | $14 |
| Qiagen, LLC | 1 | $14 |
| Exact Sciences | 1 | $13 |
| Genentech USA, Inc. | 1 | $13 |
How this compares
$2,493 in reported general payments places this provider in the 80th percentile of 496 internal medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 53 | $59,627 |
| MounjaroTirzepatide | 30 | $40,498 |
| Repatha SureclickEvolocumab | 54 | $36,418 |
| OzempicSemaglutide | 14 | $23,581 |
| CreonLipase/Protease/Amylase | 12 | $16,209 |
| JanuviaSitagliptin Phosphate | 11 | $12,730 |
| TrulicityDulaglutide | 12 | $11,911 |
| Bydureon BciseExenatide Microspheres | 12 | $9,766 |
| XareltoRivaroxaban | 12 | $6,423 |
| Rosuvastatin Calcium | 310 | $4,315 |
| Colesevelam Hcl | 12 | $4,293 |
| Levothyroxine Sodium | 294 | $2,924 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,494 |
| Potassium Chloride | 78 | $2,361 |
| SynthroidLevothyroxine Sodium | 33 | $2,142 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $86 | $59,62753 claims |
| Lilly USA, LLCMounjaro, Trulicity | $164 | $52,40942 claims |
| Novo NordiskOzempic | $95 | $23,58114 claims |
| AbbVieCreon, Synthroid | $198 | $18,35145 claims |
| MerckJanuvia | $451 | $12,73011 claims |
| Johnson & JohnsonXarelto | $54 | $6,42312 claims |
| AstraZenecaSymbicort | $26 | $2,49411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 496 internal medicine providers in Utah.
Other internal medicine in Salt Lake City
- Ahad SabetSalt Lake City$34.5M
- Willard DereSalt Lake City$4.7M
- Brandon WebbSalt Lake City$544K
- Larry StakerSalt Lake City$441K
- Alexander PastuszakSalt Lake City$197K
- Lowell BensonSalt Lake City$183K
- Gerald GleichSalt Lake City$119K
- James ChamberlainSalt Lake City$106K
- Zameer AbedinSalt Lake City$83K
- Brian HornerSalt Lake City$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.